The FDA approved subcutaneous nivolumab for solid tumors, tiselizumab for advanced gastric and GEJ cancers, and key 2024 breast cancer breakthroughs are reviewed. Experts provide perspective on ...

Cancer is one of the leading causes of death globally, and its prevalence continues to grow. While genetics and various ...